Selecting antigens for cancer vaccines

Nature Biotechnology

Volumn 30, Issue 4, 2012, Pages 328-329

  Avogadri, Francesca ^a   Wolchok, Jedd D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; CYTOCHROME C1; CYTOCHROME C1 PLUS NRAS PROTEIN PLUS TYRP1 PROTEIN; CYTOKINE; DNA VACCINE; GLYCOPROTEIN GP 100; INTERLEUKIN 17; IPILIMUMAB; NRAS PROTEIN; SIPULEUCEL T; TUMOR ANTIGEN; TYRP1 PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR; WHOLE CELL VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; DNA LIBRARY; DRUG POTENTIATION; DRUG SCREENING; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MELANOMA; NEOPLASM; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT SURVEY; TH17 CELL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; INTERLEUKIN-17; MELANOMA; NEOPLASMS, EXPERIMENTAL;

EID: 84859638529     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2174     Document Type: Short Survey

References (11)

1. Le, D.T., Pardoll, D.M. & Jaffee, E.M. Cancer J. 16, 304-310 (2010).
2. Kottke, T. et al. Nat. Med. 17, 854-859 (2011).
3. Vile, R. et al. Nat. Biotechnol. 30, 337-343 (2012).
4. Naftzger, C. et al. Proc. Natl. Acad. Sci. USA 93, 14809-14814 (1996).
5. Muranski, P. et al. Blood 112, 362-373 (2008).
6. Avogadri, F. et al. PLoS One 5, e12670 (2010).
7. Sharma, P., Wagner, K., Wolchok, J.D. & Allison, J.P. Nat. Rev. Cancer 11, 805-812 (2011).
8. Quezada, S.A., Peggs, K.S., Curran, M.A. & Allison, J.P. J. Clin. Invest. 116, 1935-1945 (2006).
9. van den Eertwegh, A.J.M. et al. Lancet Oncol., published online, doi:10.1016/S1470-2045 (10 February 2012).
10. Schwartzentruber, D.J. et al. N. Engl. J. Med. 364, 2119-2127 (2011).
11. Hodi, F.S. et al. N. Engl. J. Med. 363, 711-723 (2010).